CGH
GMED icon

Crossmark Global Holdings’s Globus Medical GMED Stock Holding History

Crossmark Global Holdings’s Portfolio GMED Stock Details GMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$696K Buy
8,809
+84
+1% +$7.14K 0.01% 754
2026
Q1 		$752K Sell
8,725
-54
-0.6% -$4.85K 0.01% 703
2025
Q4 		$766K Buy
8,779
+223
+3% +$16.9K 0.01% 696
2025
Q3 		$490K Buy
8,556
+403
+5% +$23.2K 0.01% 908
2025
Q2 		$481K Buy
8,153
+142
+2% +$9.17K 0.01% 900
2025
Q1 		$586K Sell
8,011
-40
-0.5% -$3.31K 0.01% 814
2024
Q4 		$666K Buy
8,051
+301
+4% +$23.7K 0.01% 719
2024
Q3 		$554K Buy
7,750
+436
+6% +$30.8K 0.01% 825
2024
Q2 		$501K Sell
7,314
-1,242
-15% -$74.2K 0.01% 832
2024
Q1 		$459K Buy
8,556
+53
+0.6% +$2.85K 0.01% 908
2023
Q4 		$453K Sell
8,503
-961
-10% -$46.8K 0.01% 891
2023
Q3 		$502K Buy
9,464
+2,417
+34% +$135K 0.01% 817
2023
Q2 		$429K Sell
7,047
-3
-0% -$171 0.01% 916
2023
Q1 		$399K Sell
7,050
-50
-0.7% -$3.21K 0.01% 917
2022
Q4 		$527K Sell
7,100
-320
-4% -$21.8K 0.01% 774
2022
Q3 		$442K Sell
7,420
-80
-1% -$4.82K 0.01% 817
2022
Q2 		$421K Sell
7,500
-170
-2% -$11.2K 0.01% 883
2022
Q1 		$566K Buy
7,670
+160
+2% +$11.1K 0.01% 850
2021
Q4 		$542K Buy
7,510
+780
+12% +$56.6K 0.01% 862
2021
Q3 		$516K Sell
6,730
-180
-3% -$14.5K 0.01% 909
2021
Q2 		$536K Buy
6,910
+390
+6% +$27.7K 0.01% 882
2021
Q1 		$402K Buy
6,520
+60
+0.9% +$3.8K 0.01% 1016
2020
Q4 		$421K Buy
6,460
+20
+0.3% +$1.15K 0.01% 917
2020
Q3 		$319K Sell
6,440
-10
-0.2% -$516 0.01% 986
2020
Q2 		$308K Sell
6,450
-50
-0.8% -$2.41K 0.01% 990
2020
Q1 		$276K Hold
6,500
– – 0.01% 894
2019
Q4 		$383K Sell
6,500
-5,990
-48% -$325K 0.01% 970
2019
Q3 		$638K Sell
12,490
-170
-1% -$8.1K 0.02% 693
2019
Q2 		$536K Sell
12,660
-413
-3% -$17.9K 0.02% 779
2019
Q1 		$646K Sell
13,073
-30
-0.2% -$1.36K 0.02% 691
2018
Q4 		$567K Buy
13,103
+1,840
+16% +$91.8K 0.02% 717
2018
Q3 		$639K Buy
11,263
+30
+0.3% +$1.58K 0.02% 798
2018
Q2 		$567K Buy
11,233
+490
+5% +$25.6K 0.02% 866
2018
Q1 		$535K Sell
10,743
-153
-1% -$7.19K 0.01% 873
2017
Q4 		$448K Buy
+10,896
New +$381K 0.01% 1078

Other funds holding GMED

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
AHIA
Andrew Hill Investment Advisors Naples, Florida $135M AUM 50.1% 1-Year Est. Return
RCM
Radnor Capital Management Wayne, Pennsylvania $712M AUM 34.39% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Crossmark Global Holdings's GMED Position: Q2 2026 in Review

Crossmark Global Holdings increased its Globus Medical (GMED) stake by 0.96% in Q2 2026, buying an estimated $7.14K and bringing the position to 8,809 shares worth $696K. The position accounts for 0.01% of the portfolio, ranked #754.

Crossmark Global Holdings first reported a position in GMED in Q4 2017 and has held it in 35 quarters since. The position peaked at $766K in Q4 2025. 55 funds tracked by Wall St. Rank hold GMED as of Q2 2026.

  • Crossmark Global Holdings held 8,809 shares of Globus Medical worth $696K as of Q2 2026.
  • Crossmark Global Holdings bought 84 Globus Medical shares in Q2 2026, an estimated $7.14K.
  • Globus Medical made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #754 holding.
  • Crossmark Global Holdings first reported a position in Globus Medical in Q4 2017 and has held it in 35 quarters since.
  • Crossmark Global Holdings's Globus Medical position peaked at $766K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held Globus Medical as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.